The death of Max Perutz

The Nobel prizewinner and eminent biologist Max Perutz has died.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

LONDON — The Nobel prizewinner and eminent biologist Max Perutz died on the morning of 6 February 2002 at the age of 87. Sir George Radda, Chief Executive of the Medical Research Council, where Max Perutz worked for many years, described Perutz as one of the 20th century's scientific giants. "The impact of Max's work remains a foundation on which science is being undertaken today. His Nobel prize winning work on protein structure is more relevant now than ever as we turn attention to the smallest building blocks of life to make sense of the human genome and mechanisms of disease." Perutz won a Nobel prize for chemistry in 1962, for determining the structure of hemoglobin, a pioneering application of X-ray crystallography to whole proteins.

Austrian-born Perutz was one of the founder members of the MRC Laboratory of Molecular Biology (LMB) in Cambridge, UK, which he chaired until 1979. But ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Kate Hooper

    This person does not yet have a bio.
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development